The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News

Liposomal Mitoxantrone Shows Early Safety Signal in Phase 2 NMOSD Trial Marco Meglio

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS Bruce Bebo, PhD, Isabella Ciccone, MPH

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS Isabella Ciccone, MPH

Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention Matt Hoffman

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

Todays Updates

More Time in Target Blood Pressure Range Cuts Recurrent Stroke After Intracerebral Hemorrhage Marco Meglio

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia Marco Meglio

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

Why PAD Goes Undetected in Advanced CKD, With Pranav Garimella, MBBS, MPH Pranav Garimella, MBBS, MPH

Calcified vessels may mask PAD on ankle brachial index testing, and Garimella says nephrologists can help catch it earlier.

AI Alerts Did Not Reduce Kidney Events, With Sandra Kane-Gill, PharmD, MS Sandra Kane-Gill, PharmD, MS

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

What MEnD-AKI Revealed About AI Alerts, With Sandra Kane-Gill, PharmD, MS Sandra Kane-Gill, PharmD, MS

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D Phoom Narongkiatikhun, MD

Phoom Narongkiatikhun, MD, discusses sleeve gastrectomy reducing LV mass, kidney volume, and albuminuria and boosting medullary FSOC in youth-onset T2D.

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

Todays Updates

More Time in Target Blood Pressure Range Cuts Recurrent Stroke After Intracerebral Hemorrhage Marco Meglio

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia Marco Meglio

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

Why PAD Goes Undetected in Advanced CKD, With Pranav Garimella, MBBS, MPH Pranav Garimella, MBBS, MPH

Calcified vessels may mask PAD on ankle brachial index testing, and Garimella says nephrologists can help catch it earlier.

AI Alerts Did Not Reduce Kidney Events, With Sandra Kane-Gill, PharmD, MS Sandra Kane-Gill, PharmD, MS

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

What MEnD-AKI Revealed About AI Alerts, With Sandra Kane-Gill, PharmD, MS Sandra Kane-Gill, PharmD, MS

In the MEnD-AKI trial, pharmacists reviewed deep learning predictions of AKI risk across 38 hospital service clusters at 8 hospitals.

Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D Phoom Narongkiatikhun, MD

Phoom Narongkiatikhun, MD, discusses sleeve gastrectomy reducing LV mass, kidney volume, and albuminuria and boosting medullary FSOC in youth-onset T2D.

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

Latest News

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

News All Time

First-in-Human Trial Begins for an Antisense Oligonucleotide in KCNT1-Related Epilepsy Marco Meglio

A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.

NeurologyLive® Friday 5 — October 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial Louie Pasculli

Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.

Nipocalimab in Myasthenia Gravis: Real-World Use, Long-Term Safety, and the Road Ahead Marco Meglio, Leonard Dragone, MD, PhD

Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.

FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis Marco Meglio

Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.

Levacetylleucine Shows Sustained Benefit at 3 Years in Niemann-Pick Disease Marco Meglio

Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.

Episode 177: Previewing the 2026 NEALS Annual Meeting Marco Meglio, Jinsy A. Andrews, MD, MSc, Nicholas Maragakis, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes]

FDA Grants Fast Track Status to EG-501 in Neuropsychiatric Lupus Marco Meglio

The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.

Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial Louie Pasculli

Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

MDS Congress 2026: Late-Breaking Data Snapshot Marco Meglio

A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.

New Phase 1 Study Tests Intrathecal Gene Therapy Agent INS1201 in Duchenne Muscular Dystrophy Marco Meglio

The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.

TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome Matt Hoffman

All 10 REVEAL Part A participants gained or regained at least 1 developmental milestone after a single intrathecal TSHA-102 dose, with no treatment-related SAEs reported.

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli

New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio

The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio

New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

Fenfluramine Shows Consistent Seizure Reduction Across Age Groups in CDKL5 Deficiency Disorder Isabella Ciccone, MPH

An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.

Recommended News For You

The origin of BPH and prostate cancer in different prostate zones and the impact on the incidence of prostate cancer

Q&A: When will individuals be able to receive customized cancer vaccines?

Smoker's Painless Skin Nodules Flag a Fatal Diagnosis

EBCC: European Breast Cancer Conference

New imaging guidelines for head and neck cancers, a step toward practice change

Nonpharmacologics May Reduce Anxiety, Depression in SUD

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

Recommended Articles For You

What You Need to Know About the Early Warning Signs of Colon Cancer  

Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care 

Connected Transfusion Monitoring: Advancing Safety and Efficacy in Blood Transfusion Practice 

New Research on Craniopharyngioma  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New Gene Therapy Nears EU Nod for Bladder Cancer

2.

Liver cancer cells under pressure: Compression can spark invasion, drug resistance and altered gene activity

3.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

4.

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

5.

The Cherenkov color image shows the possibility of improving the quality of radiation therapy.

1.

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis

2.

Teaching Coagulation Pathways Through Interactive Thrombin Generation Models

3.

Practical Concepts in Hematology and Patient Outcomes

4.

Contemporary Insights in Oncology in the Digital Era

5.

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Advances in Modern Cancer Treatment

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

3.

Case-Based Learning: Oncology

4.

Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot